moderna goldman sachs

Moderna Stock Falls

Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Hosted on MSN · 2d

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Seeking Alpha on MSN · 2d

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

1don MSN

Why Moderna (MRNA) Crashed on Wednesday?

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

23h

Moderna (MRNA) Receives a Hold from Bernstein

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Nasdaq4d

Goldman Sachs Downgrades Moderna (BIT:1MRNA)

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BIT:1MRNA) from Buy to Neutral. As of January 28, 2025, the average one-year price target for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results